[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341675-105":59,"doc-detail-341675-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-current-status-and-future-of-targeted-immune-combination-for-hepatocellular-carcinoma-review","The current status and future of targeted-immune combination for hepatocellular carcinoma - Review","","A review evaluates the current status and future prospects of targeted-immune combination strategies for hepatocellular carcinoma (HCC), with emphasis on advanced or unresectable disease. It explains how the liver tumor microenvironment promotes immune suppression and highlights immune-checkpoint escape mechanisms involving PD-1/PD-L1 and CTLA-4. Using evidence from the past five years, it summarizes progress with immune checkpoint inhibitors (ICIs) as monotherapy or combined regimens, especially ICIs paired with targeted and anti-angiogenic therapies, and outlines directions for next-generation clinical development.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-current-status-and-future-of-targeted-immune-combination-for-hepatocellular-carcinoma-review/341675/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-current-status-and-future-of-targeted-immune-combination-for-hepatocellular-carcinoma-review/341675.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is advanced hepatocellular carcinoma difficult to treat with current options?","Question",{"text":113,"@type":114},"Advanced HCC has a high propensity for invasion, metastasis, and recurrence, leading to low overall survival, high mortality, and poor prognosis.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What immune escape mechanisms are emphasized in hepatocellular carcinoma?",{"text":118,"@type":114},"Immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4, together with immunosuppressive cytokines, inhibit T-cell activity and drive immune escape.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are targeted-immune combinations being explored instead of relying on ICI monotherapy?",{"text":122,"@type":114},"Not all HCC patients respond to immunotherapy, and ICI monotherapy shows lower objective response rates with no significant overall survival improvement, motivating more effective combination approaches.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341675,1790144597,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 05 August 2024  \nDOI 10.3389/fimmu.2024.1418965  \nOPEN ACCESS  \nEDITED BY  \nJaya Lakshmi Thangaraj, University of California, San Diego, United States  \nREVIEWED BY Junpeng Luo,  \nHenan University, China Yuzhu Dai,  \nThe 903rd Hospital of the PLA, China  \n*CORRESPONDENCE Xiaoyu Hu  \n[xiaoyuhu202206@163.com](xiaoyuhu202206@163.com)[ ](xiaoyuhu202206@163.com)Xiaopeng Huang  \n [181489184@qq.com](181489184@qq.com)  \n†These authors have contributed equally to this work  \nRECEIVED 17 April 2024  \nACCEPTED 23 July 2024  \nPUBLISHED 05 August 2024  \nCITATION  \nHao L, Li S, Ye F, Wang H, Zhong Y, Zhang X, Hu X and Huang X (2024) The current status and future of targeted-immune combination for hepatocellular carcinoma.  \nFront. Immunol. 15:1418965 .  \ndoi: 10.3389/fimmu.2024.1418965  \nCOPYRIGHT  \n© 2024 Hao, Li, Ye, Wang, Zhong, Zhang, Hu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe current status and future of targeted-immune combination for hepatocellular carcinoma  \nLiyuan Hao 1,2†, Shenghao Li 1,2†, Fanghang Ye 1,2, Hengyi Wang 1,2  \n,  \nYuxin Zhong1,2, Xiaoyi Zhang 1,2, Xiaoyu Hu 2* and Xiaopeng Huang 3*  \n1Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China, 2 Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China, 3 Department of Urology/Andrology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China  \nHepatocellular carcinoma (HCC) is one of the most common cancersand the third leading cause of death [worldwide. surgery](worldwide. surgery), transarterial che moembolization (TACE), systemic therapy, local ablation therapy, radiotherapy, and targeted drug therapy with agents such as sorafenib. However, the tumor microenvironment of liver cancer has a strong immunosuppressive effect. Therefore, new treatments for liver cancer are still necessary. Immune checkpoint molecules, such as programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), along with high levels of immunosuppressive cytokines, induce T cell inhibition and are key mechanisms of immune escape in HCC. Recently, immunotherapy based on immune checkpoint inhibitors (ICIs) as monotherapy or in combination with tyrosine kinase inhibitors, anti-angiogenesis drugs, chemotherapy agents, and topical therapies has offered great promise in the treatment of liver cancer. In this review, we discuss the latest advances in ICIs combined with targeted drugs (targeted-immune combination) and other targeted-immune combination regimens for the treatment of patients with advanced HCC (aHCC) or unresectable HCC (uHCC), and provide an outlook on future prospects. The literature reviewed spans the last ﬁve years and includes studies identiﬁed using keywords such as “hepatocellular carcinoma,”“immune checkpoint inhibitors,” “targeted therapy,” “combination therapy,”and “immunotherapy”.  \nKEYWORDS  \nHCC, ICIS, targeted-immune combination, anti-PD-1, anti-PD-L1, CTLA-4  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nLiver cancer is the sixth most common malignancy and the third leading cause of cancer-related death worldwide (1) . Currently, hepatocellular carcinoma (HCC) accounts for about 75-85% of primary liver cancer, and is among the most common malignant tumors, posing a serious threat to public health (2) . The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly recommended staging system for HCC. Base","cbCaidy5vfexKXMz","https://ap.wps.com/l/cbCaidy5vfexKXMz","pdf",1661527,18,"English","# Introduction\n## Treatment landscape for HCC\n## Rationale for ICIs and combination therapy","[{\"question\":\"Why is advanced hepatocellular carcinoma difficult to treat with current options?\",\"answer\":\"Advanced HCC has a high propensity for invasion, metastasis, and recurrence, leading to low overall survival, high mortality, and poor prognosis.\"},{\"question\":\"What immune escape mechanisms are emphasized in hepatocellular carcinoma?\",\"answer\":\"Immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4, together with immunosuppressive cytokines, inhibit T-cell activity and drive immune escape.\"},{\"question\":\"Why are targeted-immune combinations being explored instead of relying on ICI monotherapy?\",\"answer\":\"Not all HCC patients respond to immunotherapy, and ICI monotherapy shows lower objective response rates with no significant overall survival improvement, motivating more effective combination approaches.\"}]","The current status and future of targeted-immune combination for hepatocellular carcinoma - Review | PDF",1790043141,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae578c8751fc490ee6d3c47152e363d9.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ff167a3c7b3d49bcd47a05b3a67d05f.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65610eba8354336a33a329dd7f1c83f1.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b08801d6d915a220035b654f5b0a3b09.webp",980,692]